SRP-9001-104 in Duchenne muscular dystrophy (DMD): Topline results were reported for three patients with DMD treated with imlifidase prior to administration of Sarepta’s ELEVIDYS in the trial.
Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of gene therapy.
High Anti-AAV Antibodies May No Longer Be a Barrier to Gene Therapy Administration
After a single dose of imlifidase, patients experienced a rapid reduction of IgG antibodies, to levels ≥95% less than baseline. In addition, pre-existing anti-AAV antibodies were reduced below a titre of 1:400, enabling treatment with ELEVIDYS. No new safety signals were observed in the trial. These first clinical data support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of gene therapies. Read More About Imlifidase.
